alnylam
The Early Development Quality Lead provides strategic quality oversight for internal and outsourced nonclinical studies, IND submissions, and biomarker development programs. This role ensures compliance with GLP, GCP, and OECD standards while managing risk, audits, and vendor quality issues across global research activities.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
8% above the average for this role
Director, GCP & GLP QA
Tango Therapeutics
Scientist for outsourcing of regulated Bioanalysis and biomarkers (12 month temporary contract)
Novo Nordisk A/S
QA Manager
Integrated Resources INC
Associate Director, GCP QA
Mirum Pharmaceuticals
Director, Toxicology Translational Science
Tarsus Pharmaceuticals
Director, Global Quality Assurance, GCP/GLP
Zenas BioPharma